UK consumer goods giant Reckitt Benckiser LLC created its K-Y-branded premature ejaculation spray without stealing trade secrets from a small pharmaceutical company, according to a jury in a New Jersey federal court.
Absorption Pharmaceuticals LLC failed to show that the information at issue was protected as a trade secret or that Reckitt acted dishonestly during the company's acquisition negotiations, according to the jury.
Las Vegas-based Absorption had sought more than $450 million in damages. Reckitt had no
In a 2017 lawsuit, Absorption claimed that its Promescent lidocaine spray could treat premature ejaculation in the same way that Viagra treated erectile dysfunction. Absorption claimed it shared secrets with Reckitt during discussions about a possible acquisition.
Senior Reckitt workers tried samples of Promescent and indicated it actually works, according to the lawsuit. Absorption allegedly supplied thousands of bottles of Promescent to Reckitt for testing, according to the lawsuit.
Reckitt and Absorption finished their negotiations in 2015, and K-Y Duration commenced production in 2016. Reckitt also allegedly coerced Amazon and Target to lower Promescent's visibility in an attempt to drive the company out of business.
Reckitt also committed fraud, according to the lawsuit, by making misleading assertions about its intentions to buy Absorption, which persuaded it to reveal its secrets and turn down an offer to be acquired by another business.
In a court filing this month, Reckitt contended that it had not misled Absorption and that it had failed to discover any stolen trade secrets.


Oil Prices Fall on U.S.-Iran Hormuz Deal Hopes
Sara Duterte Posts Bail Over Grave Threats Case
Mahmoud Khalil Sues Columbia Over Alleged Pro-Palestinian Harassment
US Appeals Court Upholds Anthropic AI Supply Chain Ban
Dollar Holds Near Two-Month High as Yen Approaches 160
Asian Stocks Fall as Bond Yields Surge Ahead of Trump-Xi Summit
3 clinical-grade skincare creams you really shouldn’t buy online
Judge Blocks Trump Rule Limiting Foreign Student Visas
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
FDA Approves Mirum’s Atebrioz for Rare Bone Disorder FOP
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
Evan Gershkovich Says FSB Set Trap for 2023 Russia Arrest
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds
Costco Revenue Beats Estimates as Inflation Drives Bulk Shopping
Mexico-US Trade Talks Delayed to October as Tariff Negotiations Continue 



